ArticleThe Journal of clinical investigation2019

Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.

Simona Stivala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.